Project Grant R43DK135281
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$687K
Awardee
Lynntech Inc. (PMVAL8J63516)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
College Station, TX, USA
Similar Awards
This Project Grant award of $305,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of an advanced wound care product for treating diabetic foot ulcers. The product utilizes a patented microneedle patch design to deliver three therapeutic agents that disinfect the wound, prevent bacterial biofilm formation, and activate the immune system to promote healing. Initial work will be conducted using skin tissue...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Gelsana Therapeutics Inc. a $649,984 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) on September 5, 2024. The purpose of this grant is to support the development of Provasliex Gel, a zwitterionic hydrogel that delivers controlled release of platelet-derived growth factor (PDGF) to address impaired wound healing associated with diabetes. The goal is to demonstrate the...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $268,377 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The University of North Texas Health Science Center at Fort Worth. The grant aims to develop and evaluate a novel device using high-frequency, low amplitude vibration (HFLAV) to accelerate healing of stage 2 diabetic foot ulcers (DFUs) and improve patient quality of life. Key objectives...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project aims to develop a novel implantable system that leverages distraction osteogenesis as a treatment for diabetic foot ulcers (DFUs). The $295,000 award, effective from December 15, 2024 to August 31, 2025, supports the design and development of a low-profile implantable transverse tibial transport device. This device integrates an active mechanical...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop a hyperstable and bioactive FGF1-FGF2 dimer formulation for effective healing of diabetic skin wounds. The $435,226 award to the University of Arkansas will fund research activities across three key objectives: Designing a hyperstable and bioactive FGF1-FGF2 dimer and its variants, Developing injectable anionic...
This $176,840 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under CFDA Program 93.859 (Biomedical Research and Research Training) supports the development of a predictive mathematical model of obesity-induced type 2 diabetes mellitus and chronic wound healing. The primary goal is to create a model that realistically represents the key physiological factors correlated with the high prevalence of diabetes and impaired wound healing in obese individuals. The...
This $367,577 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to Adepthera LLC aims to develop a regenerative peptide therapy to accelerate pressure ulcer healing. Specifically, the award will fund research to identify an optimal formulation of a self-assembling adrenomedullin (ADM) analog gel that can improve local blood circulation and wound healing in aging and diabetic mouse models. The proposed therapy would be administered weekly or biweekly via...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,136,156 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Visionquest Biomedical Inc., a small disadvantaged and veteran-owned business located in Albuquerque, New Mexico. The funding will support the development of an integrated smartphone-based system for the quantitative detection of diabetic peripheral neuropathy (DPN) in underserved communities. The project...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $469,682 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a 5-year period from August 1, 2024 to May 31, 2029. The grant funds research to develop a novel phototherapy approach using a bacterial metabolite, glutamate 1-semialdehyde (GSA), to diagnose,...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Emory University a 5-year, $555,034 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund the "Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation (CARE-D-FOOT-NAV)" randomized controlled trial. The project aims to assess the effectiveness of a patient navigator program in improving diabetic foot ulcer...